Ethynodiol Diacetate

Summary

Ethynodiol Diacetate (CHEMBL1200624) is an approved small-molecule estrogen receptor modulator (ATC G03DC06).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G03DC06
• Clinical trials: 1
• Chemistry: 384.5 Da · C24H32O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200624
Name	Ethynodiol Diacetate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9270
ChEBI	CHEBI:31580
ATC	G03DC06
Molecular formula	C24H32O4
Molecular weight	384.5
InChIKey	ONKUMRGIYFNPJW-KIEAKMPYSA-N

SMILES: CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C

IUPAC name: [(3S,8R,9S,10R,13S,14S,17R)-17-acetyloxy-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate

Pharmacological roles (ChEBI): estrogen receptor modulator, contraceptive drug, synthetic oral contraceptive.

Also known as: Ethynodiol diacetate, Ethynodiol diacetate component of kelnor, Ethynodiol diacetate component of ovulen, Ethynodiol diacetate component of zovia, Etinodiol, Etynodiol, Etynodiol acetate, Etynodiol diacetate, Femulen, NSC-759288, SC 11800, SC-11800

Patent coverage: 1,661 distinct patent families (5,941 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Nuclear receptor ROR-gamma, Androgen receptor, Amine oxidase [flavin-containing] A, Estrogen receptor, Progesterone receptor, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Alpha-1A adrenergic receptor, 3’,5’-cyclic-AMP phosphodiesterase 4A, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	7.89	AC50	12.9	nM	CHEMBL_ACT_25204204
AR	6.23	AC50	583.7	nM	CHEMBL_ACT_25203271
P15207	5.68	Ki	2067	nM	CHEMBL_ACT_7665191
ADORA3	5.54	AC50	2849	nM	CHEMBL_ACT_25198650
PDE4A	5.51	AC50	3094	nM	CHEMBL_ACT_25207000
P15207	5.51	IC50	3100	nM	CHEMBL_ACT_7665190
MAOA	5.37	IC50	4290	nM	CHEMBL_ACT_7663083
CHRM1	5.2	AC50	6256	nM	CHEMBL_ACT_25210138
ESR1	5	AC50	10110	nM	CHEMBL_ACT_25138771

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01359163	PHASE1	COMPLETED	A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).